ImCheck Therapeutics Company

ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.

Founded Date: 2015-01-01
Funding Status: Early Stage Venture
Total Funding: $78 381 002
Headquarters: Marseille, Provence-Alpes-Cote d'Azur, France
Last Funding Date: 2019-12-04
Last Funding Type: Series B
Estimated Revenue: Less than $1M
Industry: Women Cancer Treatment